What is the target of cabozantinib?

Cabozantinib (Cabozantinib), as an innovative multi-target tyrosine kinase inhibitor, plays an important role in anti-tumor treatment. Its unique mechanism of action lies in its ability to inhibit the activity of multiple tyrosine kinase receptors, thereby blocking the signal transduction pathways of tumor cells and inhibiting the growth and proliferation of tumor cells.

Cabotinib has a wide range of targets, including but not limited toMET, VEGFR1/2/3, ROS1, RET, AXL, NTRK, KIT and at least nine other targets. These targets play key roles in the growth, invasion, and metastasis of tumor cells. For example, VEGFR (vascular endothelial growth factor receptor) is closely related to tumor angiogenesis. By inhibiting the activity of VEGFR, cabozantinib can effectively reduce the blood supply of tumors and inhibit tumor growth. Targets such as MET, ROS1, and RET are related to the occurrence and development of various solid tumors. Cabozantinib can directly act on tumor cells and exert anti-tumor effects by inhibiting the activity of these targets.

It is worth noting that cabozantinib’s multi-target inhibitory effect enables it to exhibit good therapeutic effects in a variety of tumor types. Currently, cabozantinib has been approved for the treatment of medullary thyroid cancer, renal cell carcinoma, hepatocellular carcinoma and other cancers, and has shown potential efficacy in other tumor types such as lung cancer and prostate cancer in clinical trials.

In general, cabozantinib exerts a wide range of anti-tumor effects by inhibiting the activity of multiple tyrosine kinase receptors and blocking the signaling pathways of tumor cells. This multi-target inhibition feature gives cabozantinib unique advantages and application prospects in anti-tumor treatment.